CA-XSOLLA
18.7.2024 14:01:34 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of its Mobile Software Development Kit (SDK). Whether you want to expand your payment options, go direct-to-consumer/out-of-store, or simply improve your game’s revenue potential, Xsolla Mobile SDK is the gateway to efficiently and effectively achieve these goals. This release introduces a pivotal solution for the DMA Age, empowering developers worldwide to seamlessly integrate their games on Android and iOS platforms with a global payment solution and web shop. Such integration significantly broadens the potential for mobile game monetization worldwide and unlocks new distribution channels. Game developers like Gaijin Network LTD (Crossout), Artstorm (Modern Warships), LINGCHAI (HONG KONG) LIMITED (Fantasy Tales: Sword and Magic), and ULTRAHORSE (SquadBlast) already use Xsolla SDK to monetize their games.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718044203/en/
(Graphic: Xsolla)
The launch of the Xsolla Mobile SDK aligns with recent legislative changes worldwide, including in the European Union, particularly the Digital Markets Act (DMA), and confirmed roll-out in Japan and the UK in 2025. This shift represents a critical development in the digital marketplace, providing developers with new monetization avenues to help drive more profits by going beyond traditional app store limitations.
Xsolla’s Mobile SDK Enables Out-of-Store Transactions
Xsolla's Mobile SDK streamlines the process for developers seeking distribution solutions outside the Google Play and App Store. The SDK enables Pay Station to be the primary option for accepting payments for out-of-store transactions. Android developers can integrate it into a self-distributed APK, distributed with channeling partners supporting alternative billing methods. It is also tailored for Web Distribution and App Marketplaces for iOS notarized Apps. Moreover, it is compatible with various game engines, from Unity to Native, making it a versatile and valuable tool for developers looking to enhance their in-game payment experience. Xsolla Mobile SDK complements a Web Shop to enhance out-of-store distribution strategies.
Xsolla’s Mobile SDK Enhances In-Store Transactions with Compliance under DMA
The SDK's features include seamless integration into games already supported by the Google Play Billing Library or Apple StoreKit integrations. Xsolla's Mobile SDK provides additional functionality or replaces billing options tailored to meet Google Play (UCB) and Apple's requirements under the Digital Markets Act (DMA). With Xsolla’s Mobile SDK, games can accept payments with 700+ local payment methods in 200+ territories.
As new regulations emerge, this SDK ensures a smooth expansion to new billing models while maintaining compliance with platform requirements powered by Xsolla Pay Station in other regions.
"With the introduction of our Mobile SDK, Xsolla reaffirms its commitment to supporting mobile game developers through the evolving digital and regulatory economy," said David Stelzer, President of Xsolla. "We're here to help developers navigate the regulatory and compliance changes easily, providing them with the tools to expand their payment options, reduce commission costs, and ultimately drive greater profitability for their mobile games."
The newly released Xsolla Mobile SDK for Android has been available for developers worldwide since today, with iOS support in early access available for those operating within the European Union.
Developers can access the SDK and detailed integration guides by visiting:
Xsolla's Developer Portal
Xsolla Mobile SDK
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718044203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom